Search

Your search keyword '"Ficarra, G."' showing total 24 results
Start Over Author "Ficarra, G." Publisher elsevier bv
24 results on '"Ficarra, G."'

1. EP10.01-019 Rowing Against Cancer: From a Support Project to a Research Program. Perspectives and Challenges of Rowing in Metastatic Lung Cancer Patients

Author

Franchina, T., primary, Ficarra, G., additional, Fugazzotto, D., additional, Bitto, A., additional, Magaudda, L., additional, Trimarchi, F., additional, Di Mauro, D., additional, Zarzana, M.A., additional, Cacciola, F., additional, Aspria, P., additional, Franchina, V., additional, and Adamo, V., additional

Published
2022
Full Text
View/download PDF

2. Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study

Author

Conte, P., Frassoldati, A., Bisagni, G., Brandes, A. A., Donadio, M., Garrone, O., Piacentini, F., Cavanna, L., Giotta, F., Aieta, M., Gebbia, V., Molino, A., Musolino, A., Ferro, A., Maltoni, R., Danese, S., Zamagni, C., Rimanti, A., Cagossi, K., Russo, A., Pronzato, P., Giovanardi, F., Moretti, G., Lombardo, L., Schirone, A., Beano, A., Amaducci, L., Bajardi, E. A., Vicini, R., Balduzzi, S., D'Amico, R., Guarneri, Falci C, V., Giarratano, T, Mcmahon, L, De Salvo GL, Dieci, Mv, Maiorana, A, Ficarra, G, Caggia, F, Grisolia, D, Bartolini, S, Lorusso, V, Ardito, R, Tartarone, A, Vanella, P, Taverniti, C, Porpiglia, M, Spanu, Pg, Biglia, N, Andreis, D, Piancastelli, A, Fedeli, A, Parra, Hs, Gambaro, Ar, Romito, S, Malossi, A, Gori, S, Miglietta, L, Del Mastro, L, Amoroso, D, Mansutti, M, Generali, D, Prati, G, Bertolini, A, Berardi, R, Zanni, A, Cottafavi, L, Bologna, A, Naso, G, Pancotti, A, Farci, D, Zoboli, A, Silva, R, Laudadio, L, Bordonaro, R, Marenco, D, Dongiovanni, V, Baldini, E, Saggia, C, Gorzegno, G, Cariello, A, Biganzoli, L, Rampello, E., Conte P., Frassoldati A., Bisagni G., Brandes A.A., Donadio M., Garrone O., Piacentini F., Cavanna L., Giotta F., Aieta M., Gebbia V., Molino A., Musolino A., Ferro A., Maltoni R., Danese S., Zamagni C., Rimanti A., Cagossi K., Russo A., Pronzato P., Giovanardi F., Moretti G., Lombardo L., Schirone A., Beano A., Amaducci L., Bajardi E.A., Vicini R., Balduzzi S., D'Amico R., and Guarneri V.

Subjects
Oncology, Time Factors, Adjuvant, Breast cancer, Cardiac safety, De-escalated treatment, Trastuzumab, Settore MED/06 - Oncologia Medica, Receptor, ErbB-2, medicine.medical_treatment, Anthracycline, 030204 cardiovascular system & hematology, Breast cancer, Antineoplastic Agents, Immunological, ErbB-2, 0302 clinical medicine, Trastuzumab, Antineoplastic Combined Chemotherapy Protocols, Clinical endpoint, Anthracyclines, skin and connective tissue diseases, Adjuvant, Mastectomy, Cardiac safety, De-escalated treatment, Hazard ratio, Hematology, Middle Aged, Chemotherapy regimen, Bridged-Ring Compound, Immunological, Local, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Female, Taxoids, Trastuzumab, adjuvant, breast cancer, cardiac safety, de-escalated treatment, Breast Neoplasm, Human, Receptor, medicine.drug, Adult, Bridged-Ring Compounds, medicine.medical_specialty, Time Factor, Socio-culturale, Breast Neoplasms, Antineoplastic Agents, Disease-Free Survival, Drug Administration Schedule, 03 medical and health sciences, Taxoid, Internal medicine, medicine, Humans, Chemotherapy, Risk factor, Aged, Neoplasm Staging, Antineoplastic Combined Chemotherapy Protocol, business.industry, medicine.disease, Cardiotoxicity, Neoplasm Recurrence, Neoplasm Recurrence, Local, business
Abstract

Background: Chemotherapy plus 1-year trastuzumab is the standard adjuvant treatment of HER2-positive breast cancer. The efficacy of less extended trastuzumab exposure is under investigation. The short-HER study was aimed to assess the non-inferiority of 9 weeks versus 1 year of adjuvant trastuzumab combined with chemotherapy. Patients and methods: HER2-positive breast cancer patients with node-positive or, if node negative, with at least one risk factor (pT>2 cm, G3, lympho-vascular invasion, Ki-67 > 20%, age 35 years, or hormone receptor negativity) were randomly assigned to receive sequential anthracycline-taxane combinations plus 1-year trastuzumab (arm A, long) or plus 9 weeks trastuzumab (arm B, short). This study was designed as a non-inferiority trial with disease-free survival (DFS) as primary end point. A DFS hazard ratio (HR)

Published
2018
Full Text
View/download PDF

3. Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era

Author

Toss, A., primary, Isca, C., additional, Venturelli, M., additional, Nasso, C., additional, Ficarra, G., additional, Bellelli, V., additional, Armocida, C., additional, Barbieri, E., additional, Cortesi, L., additional, Moscetti, L., additional, Piacentini, F., additional, Omarini, C., additional, Andreotti, A., additional, Gambini, A., additional, Battista, R., additional, Dominici, M., additional, and Tazzioli, G., additional

Published
2021
Full Text
View/download PDF

4. Immune infiltrate composition across intrinsic subtypes in hormone receptor (HR)+/HER2- early breast cancer (BC) enrolled in the prospective LETLOB trial

Author

Griguolo, G., primary, Dieci, M.V., additional, Paré, L., additional, Miglietta, F., additional, Generali, D.G., additional, Frassoldati, A., additional, Bisagni, G., additional, Piacentini, F., additional, Tagliafico, E., additional, Cagossi, K., additional, Ficarra, G., additional, Prat, A., additional, Conte, P.F., additional, and Guarneri, V., additional

Published
2019
Full Text
View/download PDF

7. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study

Author

Dieci, M.V., primary, Criscitiello, C., additional, Goubar, A., additional, Viale, G., additional, Conte, P., additional, Guarneri, V., additional, Ficarra, G., additional, Mathieu, M.C., additional, Delaloge, S., additional, Curigliano, G., additional, and Andre, F., additional

Published
2015
Full Text
View/download PDF

8. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study

Author

Dieci, M.V., primary, Criscitiello, C., additional, Goubar, A., additional, Viale, G., additional, Conte, P., additional, Guarneri, V., additional, Ficarra, G., additional, Mathieu, M.C., additional, Delaloge, S., additional, Curigliano, G., additional, and Andre, F., additional

Published
2014
Full Text
View/download PDF

14. Positive predictive value for malignancy on surgical excision of breast lesions of uncertain malignant potential (B3) diagnosed by stereotactic vacuum-assisted needle core biopsy (VANCB): A large multi-institutional study in Italy

Author

Bianchi, S., primary, Caini, S., additional, Renne, G., additional, Cassano, E., additional, Ambrogetti, D., additional, Cattani, M.G., additional, Saguatti, G., additional, Chiaramondia, M., additional, Bellotti, E., additional, Bottiglieri, R., additional, Ancona, A., additional, Piubello, Q., additional, Montemezzi, S., additional, Ficarra, G., additional, Mauri, C., additional, Zito, F.A., additional, Ventrella, V., additional, Baccini, P., additional, Calabrese, M., additional, and Palli, D., additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results